Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2391 to 2400 of 2706 total matches.
Red Yeast Rice
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009 (Issue 1320)
by weight from 0% to
0.58%.
1
In another, among 10 such products, monacolin K content varied 100-fold.
2 ...
Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product to lower cholesterol.
Plerixafor (Mozobil)
The Medical Letter on Drugs and Therapeutics • Apr 05, 2010 (Issue 1335)
with G-CSF alone.
1
MECHANISM OF ACTION — Plerixafor is a small-molecule bicyclam derivative ...
The FDA has approved plerixafor (Mozobil – Genzyme), a CXCR4 chemokine receptor antagonist, for use in combination with granulocyte-colony stimulating factor (G-CSF; Neupogen) to mobilize peripheral blood stem cells in adults with multiple myeloma or non-Hodgkin’s lymphoma before high-dose chemotherapy with autologous stem cell rescue.
Risks of Tramadol and Gabapentin Use for Pain
The Medical Letter on Drugs and Therapeutics • Feb 02, 2026 (Issue 1747)
for treatment of chronic pain despite reports
of serious adverse events associated with their use.1
Both drugs ...
Tramadol (Ultram, and others) and gabapentin
(Neurontin, and others) are increasingly being
prescribed for treatment of chronic pain despite reports
of serious adverse events associated with their use.
Both drugs are touted as safer and less addictive than
strong opioids, but supporting evidence is lacking.
Med Lett Drugs Ther. 2026 Feb 2;68(1747):22-4 doi:10.58347/tml.2026.1747d | Show Introduction Hide Introduction
Posaconazole (Noxafil) for Invasive Fungal Infections
The Medical Letter on Drugs and Therapeutics • Nov 20, 2006 (Issue 1248)
of other fungal infections, including those caused by Mucor and other
Zygomycetes.
1
of candidiasis ...
Posaconazole (Noxafil - Schering-Plough), an oral azole antifungal with a chemical structure similar to that of itraconazole (Sporanox), has been approved by the FDA to prevent Candida and Aspergillus infections in severely immunocompromised patients and for treatment of oropharyngeal candidiasis. It is likely also to be used off-label for treatment of other fungal infections, including those caused by Mucor and other Zygomycetes.
Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
or T. mentagrophytes.1 About
10% of all persons worldwide and 40% of those ≥60
years old are believed ...
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include older age, diabetes, poor peripheral
circulation, smoking, HIV infection, psoriasis, and
immunosuppression. Left untreated, onychomycosis
can cause nail plate destruction, ingrown nails, and
(particularly in patients with diabetes) secondary
infections. Guidelines on treatment of onychomycosis
have been published.
Correction: Drugs for Helicobacter pylori Infection
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
as stated in
footnote 1. The footnote has been corrected and the price of the
generic formulation ...
In Table 3 on page 116 (Med Lett Drugs Ther 2017; 59:113), the price provided for Prevpac was for a 14-day supply, rather than for a 10-day supply as stated in footnote 1. The footnote has been corrected and the price of the generic formulation of Prevpac has been added.
Correction: Pitavastatin (Livalo) - The Seventh Statin
The Medical Letter on Drugs and Therapeutics • Aug 09, 2010 (Issue 1344)
have been 30- ...
In issue 1343, the usual decrease in LDL-cholesterol with pitavastatin (Livalo) in the table on page 58 should have been 35-40% with 2 mg and 40-45% with 4 mg. Also, in the paragraph on Dosage and Administration, the definition of moderately decreased renal function should have been 30-<60 mL/min/1.73 m2.
Correction: Abuse-Deterrent Opioids
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
-deterrent opioids, the information on
Targiniq ER in Table 1 is incorrect. The drug, which is not available ...
In our article on abuse-deterrent opioids (Med Lett Drugs Ther 2017; 59:95), the information on Targiniq ER in Table 1 is incorrect. The drug, which is not available in the US, is a combination of oxycodone ER and naloxone, not naltrexone, and naloxone is dispersed throughout the tablet, not sequestered. Targiniq ER will be deleted from the table in the article as it appears on our website.
Doxacurium
The Medical Letter on Drugs and Therapeutics • Jul 26, 1991 (Issue 849)
or omission. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
Doxacurium (Nuromax - Burroughs Wellcome), a new, long-acting, nondepolarizing neuromuscular blocking agent, is now available in the USA for use as a skeletal muscle relaxant during general anesthesia and for endotracheal intubation. Although small decreases in heart rate and mean arterial pressure occur in some patients who receive doxacurium, clinical studies have found no adverse cardiovascular effects in patients with heart disease receiving up to three times the usual effective dose (CM Stoops et al, Anesthesiology, 69:365, 1988; DJ Murray et al, Anesthesiology, 69:472, 1988; RS...
Idarubicin
The Medical Letter on Drugs and Therapeutics • Sep 06, 1991 (Issue 852)
. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http ...
Idarubicin hydrochloride (Idamycin - Adria), an anthracycline structurally related to daunorubicin (Cerubidine, and others) and doxorubicin (Adriamycin, and others), was recently approved in the USA for treatment of acute myelogenous leukemia (AML) in adults.
